Learning from the placenta: Acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health

Hypertension

Volumn 56, Issue 6, 2010, Pages 1026-1034

  Staff, Anne Cathrine ^a,b   Dechend, Ralf ^c,d   Pijnenborg, Robert ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c FRANZ VOLHARD CLINIC   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CELL INTERACTION; FEMALE; HUMAN; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE; TROPHOBLAST; UTERINE ARTERY;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA; PLAQUE, ATHEROSCLEROTIC; PRE-ECLAMPSIA; PREGNANCY; TROPHOBLASTS; UTERINE ARTERY; UTERUS;

EID: 78650417944     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.157743     Document Type: Review

References (127)

1. Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. Science. 2005;308:1592-1594.
2. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull. 2003;67:161-176.
3. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365: 785-799.
4. American College of Obstetricians and Gynecologists. ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet. 2002;77:67-75.
5. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499-506.
6. Roberts JM, Redman CWG. Preeclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447-1451.
7. Spargo B, McCartney CP, Winemiller R. Glomerular capillary endothe-liosis in toxemia of pregnancy. Arch Pathol. 1959;68:593-599.
8. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534-543.
9. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997;277: 1669-1672.
10. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci (Lond). 1996;91: 711-718.
11. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222:222-235.
12. Lee VM, Quinn PA, Jennings SC, Ng LL. Neutrophil activation and production of reactive oxygen species in pre-eclampsia. J Hypertens. 2003;21:395-402.
13. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol. 2003;59:153-160.
14. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
15. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. (Pubitemid 43865232)
16. Herse F, Staff AC, Hering L, Muller DN, Luft FC, Dechend R. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med. 2008;86:697-703.
17. Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynecol. 2003;15:465-471.
18. Roberts JM, Gammill H. Pre-eclampsia and cardiovascular disease in later life. Lancet. 2005;366:961-962.
19. Newstead J, von DP, Magee LA. Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther. 2007;5:283-294.
20. Magee LA, von DP. Pre-eclampsia and increased cardiovascular risk. BMJ. 2007;335:945-946.
21. Rosing U, Samsioe G, Olund A, Johansson B, Kallner A. Serum levels of apolipoprotein A-I, A-II and HDL-cholesterol in second half of normal pregnancy and in pregnancy complicated by pre-eclampsia. Horm Metab Res. 1989;21:376-382.
22. Hubel CA, Lyall F, Weissfeld L, Gandley RE, Roberts JM. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism. 1998;47: 1281-1288.
23. Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol. 1997;89:403-408.
24. Wetzka B, Winkler K, Kinner M, Friedrich I, Marz W, Zahradnik HP. Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. Semin Thromb Hemost. 1999;25:455-462.
25. Ware-Jauregui S, Sanchez SE, Zhang C, Laraburre G, King IB, Williams MA. Plasma lipid concentrations in pre-eclamptic and normotensive Peruvian women. Int J Gynaecol Obstet. 1999;67:147-155.
26. Potter JM, Nestel PJ. The hyperlipidemia of pregnancy in normal and complicated pregnancies. Am J Obstet Gynecol. 1979;133:165-170.
27. Al MD, Van Houwelingen AC, Kester AD, Hasaart TH, de Jong AE, Hornstra G. Maternal essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid status. Br J Nutr. 1995;74:55-68.
28. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Am J Obstet Gynecol. 1996;174:975-982.
29. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet. 1994;343:645-646.
30. Ogura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. J Atheroscler Thromb. 2002;9:42-47.
31. Qiu C, Phung TT, Vadachkoria S, Muy-Rivera M, Sanchez SE, Williams MA. Oxidized low-density lipoprotein (oxidized LDL) and the risk of preeclampsia. Physiol Res. 2006;55:491-500.
32. Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gynecol. 1995;85:353-356.
33. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A, Shakir AS, Seely EW, Roberts JM, Sukhatme VP, Karumanchi SA, Thadhani R. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004;89:6239-6243.
34. Pipe NG, Smith T, Halliday D, Edmonds CJ, Williams C, Coltart TM. Changes in fat, fat-free mass and body water in human normal pregnancy. Br J Obstet Gynaecol. 1979;86:929-940.
35. Coleman RA, Haynes EB. Synthesis and release of fatty acids by human trophoblast cells in culture. J Lipid Res. 1987;28:1335-1341.
36. Lorentzen B, Drevon CA, Endresen MJ, Henriksen T. Fatty acid pattern of esterified and free fatty acids in sera of women with normal and pre-eclamptic pregnancy. Br J Obstet Gynaecol. 1995;102:530-537.
37. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002;187: 127-136.
38. Gratacos E, Casals E, Sanllehy C, Cararach V, Alonso PL, Fortuny A. Variation in lipid levels during pregnancy in women with different types of hypertension. Acta Obstet Gynecol Scand. 1996;75:896-901.
39. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
40. Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, Harlap S. Long-term mortality after preeclampsia. Epidemiology. 2005;16: 206-215.
41. Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486-1491.
42. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
43. Ness RB, Hubel CA. Risk for coronary artery disease and morbid preeclampsia: a commentary. Ann Epidemiol. 2005;15:726-733.
44. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797-1803.
45. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey SG, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ. 2007;335:978.
46. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation. 2010;122:579-584.
47. Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci. 2007;334:291-295.
48. Barden A. Pre-eclampsia: contribution of maternal constitutional factors and the consequences for cardiovascular health. Clin Exp Pharmacol Physiol. 2006;33:826-830.
49. Tenhola S, Rahiala E, Martikainen A, Halonen P, Voutilainen R. Blood pressure, serum lipids, fasting insulin, and adrenal hormones in 12-year-old children born with maternal preeclampsia. J Clin Endocrinol Metab. 2003; 88:1217-1222.
50. Vatten LJ, Romundstad PR, Holmen TL, Hsieh CC, Trichopoulos D, Stuver SO. Intrauterine exposure to preeclampsia and adolescent blood pressure, body size, and age at menarche in female offspring. Obstet Gynecol. 2003;101:529-533.
51. Innes KE, Byers TE. Preeclampsia and breast cancer risk. Epidemiology. 1999;10:722-732.
52. Troisi R, Potischman N, Johnson CN, Roberts JM, Lykins D, Harger G, Markovic N, Siiteri P, Hoover RN. Estrogen and androgen concentrations are not lower in the umbilical cord serum of pre-eclamptic pregnancies. Cancer Epidemiol Biomarkers Prev. 2003;12:1268-1270.
53. Ros HS, Lichtenstein P, Ekbom A, Cnattingius S. Tall or short Twenty years after preeclampsia exposure in utero: comparisons of final height, body mass index, waist-to-hip ratio, and age at menarche among women, exposed and unexposed to preeclampsia during fetal life. Pediatr Res. 2001;49:763-769.
54. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol. 2006;49:270-283.
55. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab. 2002;13:364-368.
56. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989;2: 577-580.
57. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995;311: 171-174.
58. Lucas A. Role of nutritional programming in determining adult morbidity. Arch Dis Child. 1994;71:288-290.
59. Briscoe TA, Rehn AE, Dieni S, Duncan JR, Wlodek ME, Owens JA, Rees SM. Cardiovascular and renal disease in the adolescent guinea pig after chronic placental insufficiency. Am J Obstet Gynecol. 2004;191: 847-855. (Pubitemid 39298121)
60. Kensara OA, Wootton SA, Phillips DI, Patel M, Jackson AA, Elia M. Fetal programming of body composition: relation between birth weight and body composition measured with dual-energy X-ray absorptiometry and anthropometric methods in older Englishmen. Am J Clin Nutr. 2005;82:980-987.
61. Ong KK, Dunger DB. Thrifty genotypes and phenotypes in the patho-genesis of type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2000; 13(suppl 6):1419-1424.
62. Bloomfield FH, Oliver MH, Giannoulias CD, Gluckman PD, Harding JE, Challis JR. Brief undernutrition in late-gestation sheep programs the hypothalamic-pituitary-adrenal axis in adult offspring. Endocrinology. 2003;144:2933-2940.
63. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) Study. Lancet. 1999;354:1234-1241.
64. Barker DJ. The developmental origins of insulin resistance. Horm Res. 2005;64(suppl 3):2-7.
65. Boyd JD, Hamilton WJ. The Human Placenta. Cambridge, United Kingdom: Heffner and Son; 1970:253-266.
66. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27:939-958.
67. Craven CM, Morgan T, Ward K. Decidual spiral artery remodelling begins before cellular interaction with cytotrophoblasts. Placenta. 1998; 19:241-252.
68. King A, Loke YW. Placental vascular remodelling. Lancet. 1997;350: 220-221.
69. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1: 177-191.
70. De Wolf F, Brosens I, Robertson WB. Ultrastructure of uteroplacental arteries. Contrib Gynecol Obstet. 1982;9:86-99.
71. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93:1049-1059.
72. Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rot-mensch S, Thaler HT, Romero R. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol. 2002;187:1137-1142.
73. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, Van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991;98:648-655.
74. Lyall F. Priming and remodelling of human placental bed spiral arteries during pregnancy-a review. Placenta. 2005;26(suppl A):S31-S36.
75. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009; 30:473-482.
76. Keogh RJ, Harris LK, Freeman A, Baker PN, Aplin JD, Whitley GS, Cartwright JE. Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor-a -related apoptosis-inducing ligand to induce smooth muscle cell death. Circ Res. 2007;100:834-841.
77. Hering L, Herse F, Verlohren S, Park JK, Wellner M, Qadri F, Pijnenborg R, Staff AC, Huppertz B, Muller DN, Luft FC, Dechend R. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension. 2008;51:554-559.
78. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005;45:742-746.
79. Geusens N, Hering L, Verlohren S, Luyten C, Drijkoningen K, Taube M, Vercruysse L, Hanssens M, Dechend R, Pijnenborg R. Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model. Placenta. 2010;31:320-326.
80. Geusens N, Verlohren S, Luyten C, Taube M, Hering L, Vercruysse L, Hanssens M, Dudenhausen JW, Dechend R, Pijnenborg R. Endovascular trophoblast invasion, spiral artery remodelling and uteroplacental hae-modynamics in a transgenic rat model of pre-eclampsia. Placenta. 2008; 29:614-623.
81. Brosens I, Renaer M. On the pathogenesis of placental infarcts in pre-eclampsia. J Obstet Gynaecol Br Commonw. 1972;79:794-799.
82. Hertig AT. Vacular pathology in hypertensive albuminuric toxemias of pregnancy. Clinics. 1945;4:602-614.
83. Zeek PM, Assali NS. Vascular changes in the decidua associated with eclamptogenic toxemia of pregnancy. Am J Clin Pathol. 1950;20: 1099-1109.
84. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol. 1967;93:581-592.
85. Labarrere CA. Acute atherosis: a histopathological hallmark of immune aggression? Placenta. 1988;9:95-108.
86. Meekins JW, Pijnenborg R, Hanssens M, Van Assche A, McFadyen IR. Immunohistochemical detection of lipoprotein(a) in the wall of placental bed spiral arteries in normal and severe preeclamptic pregnancies. Placenta. 1994;15:511-524. (Pubitemid 24239619)
87. Hanssens M, Pijnenborg R, Keirse MJ, Vercruysse L, Verbist L, Van Assche FA. Renin-like immunoreactivity in uterus and placenta from normotensive and hypertensive pregnancies. Eur J Obstet Gynecol Reprod Biol. 1998;81:177-184.
88. Pijnenborg R, McLaughlin PJ, Vercruysse L, Hanssens M, Johnson PM, Keith JC Jr, Van Assche FA. Immunolocalization of tumour necrosis factor-a (TNF-a) in the placental bed of normotensive and hypertensive human pregnancies. Placenta. 1998;19:231-239.
89. Harsem NK, Roald B, Braekke K, Staff AC. Acute atherosis in decidual tissue: not associated with systemic oxidative stress in preeclampsia. Placenta. 2007;28:958-964.
90. Staff AC, Ranheim T, Halvorsen B. Augmented PLA2 activity in preeclamptic decidual tissue-a key player in the pathophysiology of 'acute atherosis' in pre-eclampsia? Placenta. 2003;24:965-973.
91. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
92. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
93. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138:S419-S420.
94. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
95. Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet. 2001;75: 243-249.
96. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol. 1995; 102:20-25.
97. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol. 1998; 40:102-111.
98. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N, Greer IA. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004;44:708-714.
99. Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-a, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58:21-30.
100. Belo L, Santos-Silva A, Caslake M, Cooney J, Pereira-Leite L, Quin-tanilha A, Rebelo I. Neutrophil activation and C-reactive protein concentration in preeclampsia. Hypertens Pregnancy. 2003;22:129-141.
101. Ustun Y, Engin-Ustun Y, Kamaci M. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;121:154-158.
102. Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC. Calpro-tectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. Am J Obstet Gynecol. 2005;193: 227-233.
103. Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96:978-982.
104. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-1504.
105. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, Toosey T, Camm AJ, Northfield TC. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30:121-128.
106. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995; 311:711-714.
107. Heine RP, Ness RB, Roberts JM. Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol. 2003;101:221-226.
108. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279: 1477-1482.
109. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
110. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int. 2001;59:407-414.
111. Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem. 2000;33:601-610.
112. Pepys MB, Berger A. The renaissance of C reactive protein. BMJ. 2001;322:4-5.
113. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, Caplice NM. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res. 2005;97:135-143.
114. Lafuente N, Azcutia V, Matesanz N, Cercas E, Rodriguez-Manas L, Sanchez-Ferrer CF, Peiro C. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol. 2005;45:193-196.
115. Van Den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol. 2004; 24:e168-e171.
116. Khong TY. Acute atherosis in pregnancies complicated by hypertension, small-for-gestational-age infants, and diabetes mellitus. Arch Pathol Lab Med. 1991;115:722-725.
117. Levy RA, Avvad E, Oliveira J, Porto LC. Placental pathology in antiphospholipid syndrome. Lupus. 1998;7(suppl 2):S81-S85.
118. Katabuchi H, Yih S, Ohba T, Matsui K, Takahashi K, Takeya M, Okamura H. Characterization of macrophages in the decidual atherotic spiral artery with special reference to the cytology of foam cells. Med Electron Microsc. 2003;36:253-262.
119. Salafia CM, Starzyk.k.a., Lage JM, Parkash V, Vercruysse L, Pijnenborg R. Lipoprotein(a) deposition in the uteroplacental bed an in basal plate uteroplacental arteries in normal and complicated pregnancies. Trophoblast Res. 1998;11:377-387.
120. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vascular growth and function in human placenta. Reproduction. 2009;138: 895-902.
121. Staff AC, Ranheim T, Khoury J, Henriksen T. Increased contents of phospholipids, cholesterol, and lipid peroxides in decidua basalis in women with preeclampsia. Am J Obstet Gynecol. 1999;180:587-592.
122. Boyd E. The lipidemia of pregnancy. J Clin Invest. 1934;13:347-363.
123. Staff AC, Halvorsen B, Ranheim T, Henriksen T. Elevated level of free 8-iso-prostaglandin F2a in the decidua basalis of women with preeclampsia. Am J Obstet Gynecol. 1999;181:1211-1215.
124. Zand T, Hoffman AH, Savilonis BJ, Underwood JM, Nunnari JJ, Majno G, Joris I. Lipid deposition in rat aortas with intraluminal hemispherical plug stenosis: a morphological and biophysical study. Am J Pathol. 1999;155:85-92.
125. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49:2379-2393.
126. Harsem NK, Staff AC, He L, Roald B. The decidual suction method: a new way of collecting decidual tissue for functional and morphological studies. Acta Obstet Gynecol Scand. 2004;83:724-730.
127. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.